REGN in the 13F filings
Regeneron Pharmaceuticals · CUSIP 75886F107
- Quarter end
- 30 Jun 2024
- the date the book describes
- Filed
- 5 Nov 2026
- latest of these filings; the earliest 26 Jul 2024
- Managers listing it
- 28
- at least, of 95 tracked, among listed positions
- Comparable managers
- 94
- filed both Q1 2024 and Q2 2024; 23 listed it in both
- Shares listed
- 24,355,261
- combined, among listed positions
- Reported value
- $25.6bn
- combined, at the quarter end
Among the 94 comparable managers: 15 buyers (opened or added shares) and 15 sellers (trimmed or exited), at least, among listed positions. Their net change in shares is not known from listed positions, because at least one of them lists it in only one of the two quarters.
Managers listing REGN in Q2 2024
28 of 28 holders
Largest increases and reductions, by shares
Increases
- Capital Research Global Investorsexisting position · 558,787 shares now+164,605
- Millennium Management LLCexisting position · 267,032 shares now+67,826
- MFS Investment Managementexisting position · 540,293 shares now+59,769
- T. Rowe Price Associates Incexisting position · 932,874 shares now+30,261
- D. E. Shaw & Co.existing position · 254,415 shares now+23,944
Reductions
- Fidelity (FMR LLC)existing position · 10,649,474 shares now-144,598
- Marshall Wace LLPexisting position · 58,873 shares now-141,514
- Invesco Ltdexisting position · 916,420 shares now-69,648
- Man Group PLCexisting position · 51,744 shares now-56,728
- Bridgewater Associates LPexisting position · 5,354 shares now-55,792
New positions and exits
New (4)
Exited (2)
- Soros Fund Management LLCwas $14m
- Winton Group Ltdwas $4.5m
Ownership over time
Tracked managers listing it, at least.
| Quarter | Holders | Reported value | Buyers | Sellers |
|---|---|---|---|---|
| Q2 2013 | 20 | $8.0bn | n.a. | n.a. |
| Q3 2013 | 19 | $10.8bn | n.a. | n.a. |
| Q4 2013 | 17 | $8.9bn | n.a. | n.a. |
| Q1 2014 | 18 | $8.8bn | n.a. | n.a. |
| Q2 2014 | 20 | $8.4bn | n.a. | n.a. |
| Q3 2014 | 22 | $10.7bn | n.a. | n.a. |
| Q4 2014 | 16 | $12.3bn | n.a. | n.a. |
| Q1 2015 | 18 | $13.2bn | n.a. | n.a. |
| Q2 2015 | 16 | $14.7bn | n.a. | n.a. |
| Q3 2015 | 21 | $12.9bn | n.a. | n.a. |
| Q4 2015 | 20 | $15.3bn | n.a. | n.a. |
| Q1 2016 | 24 | $11.3bn | n.a. | n.a. |
| Q2 2016 | 20 | $10.5bn | n.a. | n.a. |
| Q3 2016 | 18 | $12.0bn | n.a. | n.a. |
| Q4 2016 | 22 | $10.4bn | n.a. | n.a. |
| Q1 2017 | 18 | $10.3bn | n.a. | n.a. |
| Q2 2017 | 23 | $13.6bn | n.a. | n.a. |
| Q3 2017 | 21 | $11.6bn | n.a. | n.a. |
| Q4 2017 | 27 | $9.4bn | n.a. | n.a. |
| Q1 2018 | 27 | $8.5bn | n.a. | n.a. |
| Q2 2018 | 24 | $9.2bn | n.a. | n.a. |
| Q3 2018 | 27 | $10.8bn | n.a. | n.a. |
| Q4 2018 | 28 | $9.9bn | n.a. | n.a. |
| Q1 2019 | 28 | $10.4bn | n.a. | n.a. |
| Q2 2019 | 29 | $8.3bn | n.a. | n.a. |
| Q3 2019 | 24 | $7.1bn | n.a. | n.a. |
| Q4 2019 | 18 | $9.0bn | n.a. | n.a. |
| Q1 2020 | 27 | $13.0bn | n.a. | n.a. |
| Q2 2020 | 23 | $19.8bn | n.a. | n.a. |
| Q3 2020 | 24 | $17.4bn | n.a. | n.a. |
| Q4 2020 | 26 | $15.2bn | n.a. | n.a. |
| Q1 2021 | 22 | $13.7bn | n.a. | n.a. |
| Q2 2021 | 27 | $15.3bn | n.a. | n.a. |
| Q3 2021 | 26 | $15.5bn | n.a. | n.a. |
| Q4 2021 | 28 | $16.3bn | n.a. | n.a. |
| Q1 2022 | 25 | $19.2bn | n.a. | n.a. |
| Q2 2022 | 26 | $16.5bn | n.a. | n.a. |
| Q3 2022 | 24 | $19.0bn | n.a. | n.a. |
| Q4 2022 | 30 | $20.2bn | n.a. | n.a. |
| Q1 2023 | 32 | $22.3bn | n.a. | n.a. |
| Q2 2023 | 28 | $18.8bn | n.a. | n.a. |
| Q3 2023 | 26 | $21.1bn | n.a. | n.a. |
| Q4 2023 | 35 | $21.9bn | 22 | 14 |
| Q1 2024 | 28 | $23.6bn | 12 | 20 |
| Q2 2024 | 28 | $25.6bn | 15 | 15 |
| Q3 2024 | 31 | $25.0bn | 17 | 15 |
| Q4 2024 | 27 | $13.8bn | 17 | 12 |
| Q1 2025 | 29 | $12.2bn | 20 | 10 |
| Q2 2025 | 32 | $9.3bn | 24 | 10 |
| Q3 2025 | 33 | $10.1bn | 22 | 12 |
| Q4 2025 | 33 | $16.3bn | 20 | 23 |
| Q1 2026 | 24 | $15.2bn | 14 | 26 |
| Q2 2026 | 22 | $10.6bn | 24 | 15 |
Compare with…
Holders over time, buyers and sellers, and the managers holding both, side by side for up to four stocks.
REGN and LLY →REGN and JNJ →REGN and VRTX →Choose a stock to compare with REGN →
How much of the picture this is
A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. It shows no shorts, cash, bonds or performance, and it is never today’s portfolio. Large books are listed to their largest positions, so a manager missing from this table may still hold a small position below that line. These are 95 tracked managers, not the institutional market.
Which funds own REGN, latest filings →Back to the 13F Explorer →